Department of Global Health and Population, Harvard TH Chan School of Public Health, Boston, MA, US, Clinical Epidemiology Unit, Department of Medicine, Solna, Karolinska Institute, Stockholm, Sweden, and Department of Global Health Policy, Graduate School of Medicine, University of Tokyo, Tokyo, Japan.
Health Economics and Process Evaluation, the George Institute for Global Health, University of New South Wales, Australia.
Br J Gen Pract. 2017 Sep;67(662):e598-e608. doi: 10.3399/bjgp17X692141. Epub 2017 Jul 31.
The 2014 guidelines on cardiovascular risk assessment and lipid modification from the National Institute for Health and Care Excellence (NICE) recommend statin therapy for adults with prevalent cardiovascular disease (CVD), and for adults with a 10-year CVD risk of ≥10%, estimated using the QRISK2 algorithm.
To determine risk factor levels required to exceed the risk threshold for statin therapy, and to estimate the number of adults in England who would require statin therapy under the guidelines.
Cross-sectional study using a sample representative of the English population aged 30-84 years.
To estimate 10-year CVD risk different combinations of risk factor levels were entered into the QRISK2 algorithm. The NICE guidelines were applied to the sample using data from the Health Survey for England 2011.
Even with optimal risk factor levels, males of different ethnicities would exceed the 10% risk threshold between the ages of 60 and 70 years, and females would exceed the threshold between 65 and 75 years. Under the NICE guidelines, 11.8 million males and females (37% of the adults aged 30-84 years) would require statin therapy, most of them (9.8 million) for primary prevention. When analysed by age, 95% of males and 66% of females without CVD in ages 60-74 years, including all males and females in ages 75-84 years, would require statin therapy.
Under the 2014 NICE guidelines, 11.8 million (37%) adults in England aged 30-84 years, including almost all males >60 years in all females >75 years, require statin therapy.
英国国家健康与临床优化研究所(NICE)2014 年心血管风险评估和血脂改善指南建议,对于有明确心血管疾病(CVD)病史的成年人,以及 QRISK2 算法预测 10 年 CVD 风险≥10%的成年人,应使用他汀类药物治疗。
确定需要超过他汀类药物治疗风险阈值的危险因素水平,并估计根据指南,英格兰需要他汀类药物治疗的成年人数量。
使用代表英格兰 30-84 岁人群的样本进行横断面研究。
为了估计 10 年 CVD 风险,我们将不同的危险因素水平组合输入 QRISK2 算法。使用来自 2011 年英格兰健康调查的数据,将 NICE 指南应用于该样本。
即使危险因素水平最优,不同种族的男性也会在 60-70 岁之间超过 10%的风险阈值,女性则会在 65-75 岁之间超过该阈值。根据 NICE 指南,1180 万男性和女性(30-84 岁成年人的 37%)需要他汀类药物治疗,其中大多数(980 万)为一级预防。按年龄分析,95%的无 CVD 的 60-74 岁男性和 66%的女性,包括所有 75-84 岁的男性和女性,都需要他汀类药物治疗。
根据 2014 年 NICE 指南,英格兰 30-84 岁的 1180 万(37%)成年人,包括所有 60 岁以上的男性和所有 75 岁以上的女性,都需要他汀类药物治疗。